Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.

It takes about 3 months to complete "active treatment" of venous thromboembolism (VTE), with further treatment serving to prevent new episodes of thrombosis ("pure secondary prevention"). Consequently, VTE should generally be treated for either 3 months or indefinitely (exceptions will be described in the text). The decision to stop anticoagulants at 3 months or to treat indefinitely is dominated by the long-term risk of recurrence, and secondarily influenced by the risk of bleeding and by patient preference. VTE provoked by a reversible risk factor, or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence and is usually treated for 3 months. VTE associated with active cancer, or a second unprovoked VTE, has a high risk of recurrence and is usually treated indefinitely. The decision to stop anticoagulants at 3 months or to treat indefinitely is more finely balanced after a first unprovoked proximal DVT or pulmonary embolism (PE). Indefinite anticoagulation is often chosen if there is a low risk of bleeding, whereas anticoagulation is usually stopped at 3 months if there is a high risk of bleeding. The decision to continue anticoagulation indefinitely after a first unprovoked proximal DVT or PE is strengthened if the patient is male, the index event was PE rather than DVT, and/or d-dimer testing is positive 1 month after stopping anticoagulant therapy.

[1]  C. Flowers,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Gary H Lyman,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Lara A. Kahale,et al.  Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2014, The Cochrane database of systematic reviews.

[4]  Mary C Politi,et al.  Importance of clarifying patients’ desired role in shared decision making to match their level of engagement with their preferences , 2013, BMJ.

[5]  Agnes Y. Y. Lee,et al.  Treatment of cancer-associated thrombosis. , 2013, Blood.

[6]  W. Olson,et al.  All-cause and disease-related health care costs associated with recurrent venous thromboembolism , 2013, Thrombosis and Haemostasis.

[7]  Chris Cameron,et al.  Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis , 2013, BMJ.

[8]  E. Akl,et al.  Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. , 2013, Blood.

[9]  E. Kuipers,et al.  New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. , 2013, Gastroenterology.

[10]  D. Coyle,et al.  Estimating quality of life in acute venous thrombosis. , 2013, JAMA internal medicine.

[11]  W. Ageno,et al.  The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study , 2013, Journal of thrombosis and haemostasis : JTH.

[12]  S. Schulman Tossing a coin or using common sense , 2013, Journal of thrombosis and haemostasis : JTH.

[13]  B. Lämmle,et al.  Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism , 2013, Journal of thrombosis and haemostasis : JTH.

[14]  S. Goldhaber,et al.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.

[15]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[16]  A. Khorana,et al.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[17]  John W. Williams,et al.  Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. , 2012, Annals of internal medicine.

[18]  D. Xavier,et al.  Low-dose aspirin for preventing recurrent venous thromboembolism. , 2012, The New England journal of medicine.

[19]  S. Kahn,et al.  Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials , 2012, BMJ : British Medical Journal.

[20]  C. Kearon,et al.  Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism , 2012, Current opinion in hematology.

[21]  J. Douketis,et al.  Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) , 2012, Journal of thrombosis and haemostasis : JTH.

[22]  W. Ageno,et al.  Aspirin for preventing the recurrence of venous thromboembolism. , 2012, The New England journal of medicine.

[23]  J. Douketis,et al.  Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH , 2012, Journal of Thrombosis and Haemostasis.

[24]  C. Kearon,et al.  A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism , 2012, Journal of thrombosis and haemostasis : JTH.

[25]  T. Bochenek,et al.  The treatment of venous thromboembolism with low-molecular-weight heparins , 2012, Thrombosis and Haemostasis.

[26]  G. Guyatt,et al.  Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[27]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[28]  G. Guyatt,et al.  ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES , 2012 .

[29]  P. Wells,et al.  Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism , 2010, Circulation.

[30]  P. Wells,et al.  Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta‐analysis , 2011, Journal of thrombosis and haemostasis : JTH.

[31]  Giancarlo Agnelli,et al.  Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials , 2011, BMJ : British Medical Journal.

[32]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[33]  Mary Cushman,et al.  Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis , 2011, BMJ : British Medical Journal.

[34]  J. Douketis,et al.  Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[35]  A. Iorio,et al.  Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. , 2010, Archives of internal medicine.

[36]  J. Douketis,et al.  Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism , 2010, Annals of Internal Medicine.

[37]  H. Tilg,et al.  Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. , 2010, Gastroenterology.

[38]  P. Wells,et al.  Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism , 2010, Annals of Internal Medicine.

[39]  Georg Heinze,et al.  Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.

[40]  B. Cosmi,et al.  Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. , 2010, Thrombosis research.

[41]  Jodi B Segal,et al.  Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. , 2009, JAMA.

[42]  S. Kahn,et al.  Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy , 2008, Canadian Medical Association Journal.

[43]  A. Kakkar Venous thromboembolism prophylaxis and treatment in patients with cancer. , 2008, Clinical advances in hematology & oncology : H&O.

[44]  D. P. Bentley,et al.  Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial , 2007, BMJ : British Medical Journal.

[45]  A. Iorio,et al.  D-dimer testing to determine the duration of anticoagulation therapy. , 2006, The New England journal of medicine.

[46]  S. Schulman,et al.  Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis , 2006, The Lancet.

[47]  O. Linder,et al.  Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months , 2006, Journal of thrombosis and haemostasis : JTH.

[48]  L. Bressollette Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave) Randomized Study , 2005, Circulation.

[49]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[50]  T. Wakefield Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran , 2004 .

[51]  Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. , 2004, Thrombosis and haemostasis.

[52]  R. Farraj Anticoagulation period in idiopathic venous thromboembolism. How long is enough? , 2004, Saudi medical journal.

[53]  J. Douketis,et al.  Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor , 2004, Journal of thrombosis and haemostasis : JTH.

[54]  S. Schulman,et al.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.

[55]  A. Iorio,et al.  Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants , 2003, Journal of thrombosis and haemostasis : JTH.

[56]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[57]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[58]  P. Wells,et al.  The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. , 2003, Archives of internal medicine.

[59]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[60]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[61]  P. Romano,et al.  Comparison of Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism , 2002, Thrombosis and Haemostasis.

[62]  P. Monagle,et al.  Post-thrombotic syndrome , 2002, Archives of disease in childhood.

[63]  W. Ageno,et al.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.

[64]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[65]  W. Ageno,et al.  Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopatic deep venous thrombosis. , 2001 .

[66]  S. Schulman,et al.  The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg , 2000, Journal of internal medicine.

[67]  H. Eriksson,et al.  Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.

[68]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[69]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[70]  L. Melton,et al.  Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. , 1999, Archives of internal medicine.

[71]  R. White,et al.  Incidence of Idiopathic Deep Venous Thrombosis and Secondary Thromboembolism among Ethnic Groups in California , 1998, Annals of Internal Medicine.

[72]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[73]  M. Gent,et al.  Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis , 1995, Thrombosis and Haemostasis.

[74]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[75]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[76]  Research Committee on Type 1 Diabetes of the Japan Diabetes Society Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism , 1992, The Lancet.

[77]  Researchcommitteeofthebritish Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism*1 , 1992 .